In What Direction Will Fate Therapeutics Inc.’s (NASDAQ:FATE) Stock Goes From Here?

The closing price of Fate Therapeutics Inc. (NASDAQ: FATE) was $19.55 for the day, down -0.46% from the previous closing price of $19.64. In other words, the price has decreased by -$0.09 from its previous closing price. On the day, 610195 shares were traded. FATE stock price reached its highest trading level at $19.68 during the session, while it also had its lowest trading level at $18.86.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.



Our analysis of FATE’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.20 and its Current Ratio is at 5.20. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

On October 10, 2022, Canaccord Genuity started tracking the stock assigning a Buy rating and target price of $42.

Insider Transactions:

Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 18 when Dulac Edward J III sold 5,135 shares for $29.81 per share. The transaction valued at 153,051 led to the insider holds 136,801 shares of the business.

Wolchko J Scott sold 6,246 shares of FATE for $200,356 on Jul 22. The President and CEO now owns 431,546 shares after completing the transaction at $32.08 per share. On Jul 21, another insider, Wolchko J Scott, who serves as the President and CEO of the company, sold 30,000 shares for $32.88 each. As a result, the insider received 986,361 and left with 431,546 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 27.86 while its Price-to-Book (P/B) ratio in mrq is 3.66.

Stock Price History:

Over the past 52 weeks, FATE has reached a high of $66.56, while it has fallen to a 52-week low of $17.10. The 50-Day Moving Average of the stock is 21.65, while the 200-Day Moving Average is calculated to be 28.36.

Shares Statistics:

FATE traded an average of 1.33M shares per day over the past three months and 1.47M shares per day over the past ten days. A total of 97.02M shares are outstanding, with a floating share count of 95.67M. Shares short for FATE as of Oct 13, 2022 were 21.78M with a Short Ratio of 22.23M, compared to 20.8M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 22.45% and a Short% of Float of 30.04%.

Earnings Estimates

The firm’s stock currently is rated by 22 analysts. On average, analysts expect EPS of -$0.89 for the current quarter, with a high estimate of -$0.77 and a low estimate of -$1.06, while EPS last year was -$0.45. The consensus estimate for the next quarter is -$0.96, with high estimates of -$0.77 and low estimates of -$1.33.

Analysts are recommending an EPS of between -$3 and -$3.9 for the fiscal current year, implying an average EPS of -$3.33. EPS for the following year is -$3.84, with 21 analysts recommending between -$2.85 and -$4.96.

Revenue Estimates

A total of 21 analysts have provided revenue estimates for FATE’s current fiscal year. The highest revenue estimate was $76.96M, while the lowest revenue estimate was $45M, resulting in an average revenue estimate of $67.09M. In the same quarter a year ago, actual revenue was $55.85M, up 20.10% from the average estimate.